MedPath

bioMérieux's BIOFIRE Tropical Fever Panel Receives FDA Clearance for Rapid Pathogen Identification

• bioMérieux's BIOFIRE FILMARRAY Tropical Fever Panel has received FDA 510(k) clearance, enabling rapid identification of pathogens causing tropical fevers. • The PCR test swiftly detects pathogens like Plasmodium species, crucial for malaria treatment, and aids in reducing inappropriate antibiotic use. • Scheduled for commercial launch in early 2025, the test promises improved patient management and public health diagnostics through timely diagnosis. • Developed in collaboration with U.S. agencies, the panel underscores the importance of public-private partnerships in advancing health innovation.

bioMérieux, a leader in in vitro diagnostics, has announced that its BIOFIRE FILMARRAY Tropical Fever Panel has received Special 510(k) clearance from the U.S. FDA. This PCR testing solution is designed for the rapid identification of pathogens in patients presenting with unexplained fevers, potentially leading to more effective and timely treatment interventions. The test addresses the critical need for swift and accurate diagnosis of tropical fevers such as malaria and dengue, which affect millions globally.
The BIOFIRE FILMARRAY Tropical Fever Panel enables healthcare providers to quickly detect pathogens commonly associated with tropical fevers. This rapid detection capability can lead to improved patient management and better clinical outcomes. A key feature of the test is its ability to differentiate between Plasmodium species, which is vital for determining the appropriate course of treatment for malaria. The system requires minimal preparation time when used with BIOFIRE systems, enhancing its utility in clinical settings.
The company plans to commercially launch the BIOFIRE FILMARRAY Tropical Fever Panel in early 2025, with broader global deployment to follow. The development of this diagnostic tool involved collaboration with U.S. agencies, highlighting the significance of public-private partnerships in driving innovation in healthcare. The test aims to address the growing need for precise identification of tropical pathogens, potentially reducing inappropriate antibiotic use and improving patient outcomes.
The BIOFIRE FILMARRAY Tropical Fever Panel is a multiplex PCR test designed to identify a range of pathogens responsible for causing tropical fevers. By providing rapid and accurate results, this test can help clinicians differentiate between various causes of fever, allowing for targeted treatment strategies. This is particularly important in regions where multiple tropical diseases may present with similar symptoms.
The introduction of this diagnostic tool is expected to play a crucial role in advancing public health diagnostics and improving patient care in areas affected by tropical diseases. The company's commitment to innovation and collaboration underscores its dedication to addressing unmet medical needs and improving global health outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

MeMed's Sepsis Severity Test Gains FDA Breakthrough Device Designation

MeMed's Severity test received FDA Breakthrough Device designation to improve management of suspected acute infections and sepsis.
The test uses host-response technology and machine learning to stratify patients' risk of severe outcomes or death.

FDA Approves AI Tool for ARIA Detection, Expands Nerivio Indication, and Grants Accelerated Approval to Gene Therapy for AADC Deficiency

The FDA cleared icobrain aria, the first AI software to detect and grade amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease, enhancing patient safety during anti-amyloid treatments.
Theranica's Nerivio receives expanded FDA approval for acute migraine treatment in patients aged 8 and older, offering a needle-free, non-drug alternative for pediatric migraine.

FDA Approves Abionic's CAPSULE PSP for Early Sepsis Detection; Fapon to Commercialize in China

Abionic's CAPSULE PSP, an early sepsis detection test, has received FDA 510(k) clearance, marking a significant advancement in sepsis diagnosis.
The test utilizes Pancreatic Stone Protein (PSP) as a biomarker, detecting sepsis 24-48 hours earlier than current standard methods, improving patient outcomes.

FDA Approves Abionic's CAPSULE PSP for Early Sepsis Detection

Abionic's CAPSULE PSP, an innovative in vitro diagnostic test for early sepsis detection, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The CAPSULE PSP test measures Pancreatic Stone Protein (PSP) levels, an emerging biomarker that can detect sepsis 24-48 hours earlier than current standard methods.

FDA Grants Priority Review to Telix's Pixclara for Glioma Imaging

The FDA has accepted Telix Pharmaceuticals' New Drug Application for TLX101-CDx (Pixclara), a PET imaging agent for glioma, granting priority review.
Pixclara targets LAT1 and LAT2, offering potential as a companion diagnostic for Telix's TLX101-Tx, currently in development for glioblastoma.

Accelerate Diagnostics' Accelerate Arc System Receives FDA Clearance for Rapid Microbial Identification

The FDA has cleared Accelerate Diagnostics' Accelerate Arc system for rapid microbial identification from positive blood cultures, aiding in sepsis management.
The system automates sample preparation for Bruker's MALDI Biotyper, reducing the need for overnight cultures and accelerating result delivery.

T2 Biosystems' T2Candida Panel Receives FDA Clearance for Pediatric Use

T2 Biosystems has received FDA clearance to market its T2Candida Panel for pediatric patients, expanding its availability to over 200 children’s hospitals in the U.S.
The T2Candida Panel detects five _Candida_ species directly from blood in 3-5 hours, significantly faster than traditional blood culture methods.

T2 Biosystems' T2Candida Panel Receives FDA Clearance for Pediatric Use

T2 Biosystems has secured FDA clearance to market its T2Candida Panel for pediatric patients, expanding its reach to over 200 children's hospitals in the U.S.
The T2Candida Panel is the only FDA-cleared diagnostic test capable of detecting sepsis-causing Candida species directly from blood within 3-5 hours.

FDA Approves Illumina's TruSight Oncology Comprehensive Assay as Pan-Tumor Companion Diagnostic

The FDA has approved Illumina's TruSight Oncology (TSO) Comprehensive Assay as a pan-tumor companion diagnostic, enhancing precision medicine.
TSO Comprehensive is the first FDA-approved kit for identifying NTRK-positive solid tumor patients eligible for larotrectinib and RET fusion-positive NSCLC patients for selpercatinib.

Medtronic's DiamondTemp Ablation System Receives FDA Approval for Atrial Fibrillation Treatment

Medtronic's DiamondTemp Ablation (DTA) system has gained FDA approval for treating recurrent, symptomatic paroxysmal atrial fibrillation (AF) in patients unresponsive to drug therapy.
The DTA system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds, offering real-time feedback for precise lesion creation.

Reference News

[1]
BIOMERIEUX (EPA:BIM) | BioMérieux's Diagnostic Test Receives FDA Clearance
webdisclosure.com · Dec 9, 2024

bioMérieux's BIOFIRE® FILMARRAY® Tropical Fever Panel received U.S. FDA Special 510(k) clearance, offering rapid PCR tes...

[2]
bioMérieux Gains FDA Clearance for Tropical Fever Test | Markets Insider
markets.businessinsider.com · Dec 9, 2024

bioMérieux’s BIOFIRE® FILMARRAY® Tropical Fever Panel, a rapid PCR test, received U.S. FDA clearance for diagnosing trop...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy